Cytosorbents Q2 Loss Widens, Going Concern Warning Reiterated, Cash Dwindles to $4.4M
CTSO is trading near its 52-week low of $0.35 (14% above the low).
Summary
Cytosorbents' Q2 2026 filing reveals a $9.5M H1 net loss, a going concern warning, and only $4.4M in unrestricted cash. Nasdaq delisting risk looms as the company fails two listing standards.
Key Events · Earnings and Guidance · CTSO
-
Going Concern Warning Reiterated
Management again expressed substantial doubt about the company's ability to continue as a going concern, with only $4.4 million in unrestricted cash as of June 30, 2026.
-
H1 2026 Net Loss of $9.5M
The company swung to a $9.5 million net loss in the first half of 2026 from a $0.5 million profit a year earlier, driven by foreign currency losses and higher interest expense.
-
Nasdaq Delisting Risk
Cytosorbents is non-compliant with both the $1.00 minimum bid price rule and the $35 million market value of listed securities rule, with compliance deadlines in September and December 2026.
-
FDA Delay Blocks Additional Funding
FDA approval of DrugSorb-ATR is now expected beyond 2026, meaning the company cannot access a $2.5 million loan tranche or extend its interest-only period, increasing liquidity pressure.
Analysis · CTSO · Industrial Applications And Services
Cytosorbents swung to a net loss of $9.5 million for the first half of 2026, reversing a small profit from the prior year, and once again flagged substantial doubt about its ability to continue as a going concern. Unrestricted cash dropped to $4.4 million, and the company acknowledged it fails two Nasdaq listing standards. While operating cash burn improved, the delay in FDA approval for its key product, DrugSorb-ATR, means it will not access an additional $2.5 million loan tranche or extend its interest-only period, intensifying near-term liquidity pressure. The stockholder deficit and unremediated material weaknesses in financial controls further elevate the risk profile.
At the time of this filing, CTSO was trading at $0.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $25M. The 52-week trading range was $0.35 to $1.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.